Defining the impact of stromal aging on ovarian cancer initiation
定义基质老化对卵巢癌发生的影响
基本信息
- 批准号:10491889
- 负责人:
- 金额:$ 45.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-30 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:5&apos-AMP-activated protein kinaseAdoptedAgeAgingBMP4Cancer Cell GrowthCancer ModelCell AgingCell secretionCellsChronicClinical TrialsColonDNA DamageDNA MethylationDataDevelopmentDiagnosisDiseaseEarly DiagnosisEpigenetic ProcessEpithelial CellsGenetically Engineered MouseGoalsGrowthHomeostasisHumanIn VitroInflammationInflammatoryLabelLiverLongevityLungMaintenanceMalignant NeoplasmsMalignant neoplasm of ovaryMammalian OviductsMediatingMesenchymalMetforminModelingMultipotent Stem CellsMusOrganoidsOvarianOvulationPatientsPatternPhenotypePrevention strategyPrognostic FactorProtein KinaseProteinsRequest for ApplicationsRisk FactorsRoleSerousSiteStromal CellsStromal ChangeTimeTissuesTransgenic MiceWT1 geneWild Type MouseWomanWorkage groupage relatedagedanti aginganti-tumor immune responsecancer cellcancer initiationcancer invasivenesschemokineepigenomicshigh riskimprovedin vivomRNA Expressionmultipotent stromal progenitornovelpremalignantpreventresponsesenescencespatial relationshipstem cellstranscription factortumor progressiontumorigenicwound healing
项目摘要
Age is a major risk factor for high grade serous ovarian cancer (HGSOC) with an average age at diagnosis of
63. Ovulation and aging induce inflammatory changes in the fallopian tube microenvironment, the origin of most
HGSOC. Over time, cells become senescent and secrete regulatory factors known as the senescence
associated secretory phenotype (SASP). SASP-induced changes in the local microenvironment have been
implicated in cancer promotion. However, the role of the aging microenvironment in ovarian cancer initiation is
unknown creating a major barrier to effective early detection and prevention strategies for this deadly disease.
The goal of this proposal is to define the impact of aging on interactions between stromal cells and cancer
initiating cells (CIC) that drive ovarian cancer formation. Mesenchymal stromal/stem cell (MSC) are multipotent
stromal progenitor cells critical to tissue homeostasis across the lifespan. In cancer, MSCs undergo epigenomic
reprogramming to become pro-tumorigenic cancer associated MSCs (CA-MSCs). The pro-tumorigenic CA-MSC
phenotype is driven by the activation of the Wilms tumor 1 (WT1) transcription factor. WT1 induces the secretion
of CA-MSC derived BMP4 which increases the pool of ovarian CICs. Preliminary data demonstrate that with
increasing age, MSCs can express WT1 and adopt a cancer promoting phenotype even before cancer starts.
We have termed these cells ‘high risk’ MSCs (hrMSCs). Preliminary data indicate that hrMSCs (i) recapitulate
the CA-MSC phenotype and are enriched in the stroma of pre-malignant epithelial cells, (ii) secrete SASP-like
proteins which both induce epithelial cell DNA damage and support the survival of DNA damaged epithelial cells
and (iii) support established cancer cell growth. AMP-activated protein kinase (AMPK) may be critical to CA-
MSC/hrMSC formation. In a clinical trial Metformin, which increases AMPK, reversed the CA-MSC phenotype in
some patients correlating with improved survival. Preliminary data shows a more potent, novel AMPK activator,
BC1618, alters the hrMSC secretome. We hypothesize that aging induces epigenetic changes which convert
MSCs to hrMSCs and that hrMSCs create a pro-tumorigenic microenvironment that supports the growth of
ovarian CICs. Our collaborative team with expertise in aging, stromal stem cells and CICs propose to: 1)
Determine the impact of aging on the fallopian tube MSC phenotype and spatial relationship to CICs. We
hypothesize that aged MSCs obtain a high risk phenotype through altered DNA methylation and support adjacent
CIC formation. 2) Determine the impact of aged hrMSCs on CIC formation and ovarian cancer progression. We
hypothesize that aged hrMSCs promote CIC formation and progression via WT1-mediated BMP4 and SASP
secretion. 3) Target aging hrMSCs to limit ovarian cancer formation. We hypothesize that the AMPK activator,
BC1618, through altering age-related MSC epigenetic changes, will decrease hrMSC formation and ovarian
cancer initiation. This work will broaden our understanding of ovarian cancer initiation by defining the critical role
of aging stroma in CIC formation and offer new avenues for early detection and prevention strategies.
年龄是高级别浆液性卵巢癌(HGSOC)的主要危险因素,诊断时的平均年龄为
63.排卵和衰老诱导输卵管微环境的炎症变化,这是大多数输卵管炎的起源。
HGSOC。随着时间的推移,细胞变得衰老并分泌称为衰老的调节因子。
相关分泌表型(SASP)。SASP引起的局部微环境的变化已经被
与癌症促进有关。然而,衰老微环境在卵巢癌发生中的作用是
这一未知因素对有效早期发现和预防这一致命疾病的战略构成了重大障碍。
这项提案的目标是确定衰老对基质细胞和癌症之间相互作用的影响
启动细胞(CIC)驱动卵巢癌形成。间充质基质/干细胞(MSC)是多能的
基质祖细胞对整个生命周期的组织稳态至关重要。在癌症中,MSC经历表观基因组
重编程以成为促肿瘤发生癌症相关MSC(CA-MSC)。促肿瘤发生CA-MSC
表型由Wilms肿瘤1(WT 1)转录因子的激活驱动。WT 1诱导分泌
CA-MSC衍生的BMP 4增加卵巢CIC的库。初步数据显示,
随着年龄的增长,MSC可以表达WT 1,甚至在癌症开始之前就采用癌症促进表型。
我们将这些细胞称为“高风险”MSC(hrMSC)。初步数据表明,hrMSC(i)概括了
CA-MSC表型,并在恶变前上皮细胞的基质中富集,(ii)分泌SASP样
诱导上皮细胞DNA损伤并支持DNA损伤的上皮细胞存活的蛋白质
和(iii)支持已建立的癌细胞生长。AMP激活的蛋白激酶(AMPK)可能是CA的关键。
MSC/hrMSC形成。在一项临床试验中,增加AMPK的Metabolic逆转了CA-MSC的表型,
一些患者的生存率提高。初步数据显示,一种更有效的新型AMPK激活剂,
BC 1618改变hrMSC分泌组。我们假设衰老诱导表观遗传变化,
我们还发现,人骨髓间充质干细胞转化为人骨髓间充质干细胞,人骨髓间充质干细胞创造了一个促肿瘤发生的微环境,支持肿瘤细胞的生长。
卵巢CIC。我们的合作团队在衰老、基质干细胞和CIC方面拥有专业知识,建议:1)
确定老化对输卵管MSC表型的影响以及与CIC的空间关系。我们
假设老化MSC通过改变DNA甲基化获得高风险表型,并支持邻近的
战斗信息中心编队。2)确定老化的hrMSCs对CIC形成和卵巢癌进展的影响。我们
推测老化hrMSCs通过WT 1介导的BMP 4和SASP促进CIC的形成和进展
分泌物3)靶向衰老的hrMSCs以限制卵巢癌的形成。我们假设AMPK激活剂,
BC 1618通过改变与年龄相关的MSC表观遗传变化,将减少hrMSC的形成和卵巢功能。
癌症起始。这项工作将扩大我们的理解卵巢癌的启动,通过定义的关键作用
衰老间质在CIC形成中的作用,并为早期检测和预防策略提供了新的途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ronald J Buckanovich其他文献
Ronald J Buckanovich的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ronald J Buckanovich', 18)}}的其他基金
Project 3: Hedgehog Inhibition to Enhance Response to ICI Therapy
项目 3:Hedgehog 抑制增强 ICI 治疗反应
- 批准号:
10713054 - 财政年份:2023
- 资助金额:
$ 45.76万 - 项目类别:
Evaluating unique aspects of quiescent ovarian cancer cell biology for therapeutic targets
评估静息卵巢癌细胞生物学的独特方面以寻找治疗靶点
- 批准号:
10750118 - 财政年份:2023
- 资助金额:
$ 45.76万 - 项目类别:
Defining the impact of stromal aging on ovarian cancer initiation
定义基质老化对卵巢癌发生的影响
- 批准号:
10353485 - 财政年份:2021
- 资助金额:
$ 45.76万 - 项目类别:
Defining the impact of stromal aging on ovarian cancer initiation
定义基质老化对卵巢癌发生的影响
- 批准号:
10659225 - 财政年份:2021
- 资助金额:
$ 45.76万 - 项目类别:
ALDH Inhibition as Modulator of Tumor Immunobiology
ALDH 抑制作为肿瘤免疫生物学的调节剂
- 批准号:
10392913 - 财政年份:2020
- 资助金额:
$ 45.76万 - 项目类别:
ALDH Inhibition as Modulator of Tumor Immunobiology
ALDH 抑制作为肿瘤免疫生物学的调节剂
- 批准号:
10380368 - 财政年份:2020
- 资助金额:
$ 45.76万 - 项目类别:
ALDH Inhibition as Modulator of Tumor Immunobiology
ALDH 抑制作为肿瘤免疫生物学的调节剂
- 批准号:
10524133 - 财政年份:2020
- 资助金额:
$ 45.76万 - 项目类别:
ALDH Inhibition as Modulator of Tumor Immunobiology
ALDH 抑制作为肿瘤免疫生物学的调节剂
- 批准号:
10649413 - 财政年份:2020
- 资助金额:
$ 45.76万 - 项目类别:
相似海外基金
Pharmacological targeting of AMP-activated protein kinase for immune cell regulation in Type 1 Diabetes
AMP 激活蛋白激酶对 1 型糖尿病免疫细胞调节的药理学靶向
- 批准号:
2867610 - 财政年份:2023
- 资助金额:
$ 45.76万 - 项目类别:
Studentship
Establishing AMP-activated protein kinase as a regulator of adipose stem cell plasticity and function in health and disease
建立 AMP 激活蛋白激酶作为脂肪干细胞可塑性和健康和疾病功能的调节剂
- 批准号:
BB/W009633/1 - 财政年份:2022
- 资助金额:
$ 45.76万 - 项目类别:
Fellowship
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
- 批准号:
532989-2019 - 财政年份:2021
- 资助金额:
$ 45.76万 - 项目类别:
Postdoctoral Fellowships
Metabolic control of integrin membrane traffic by AMP-activated protein kinase controls cell migration.
AMP 激活的蛋白激酶对整合素膜运输的代谢控制控制着细胞迁移。
- 批准号:
459043 - 财政年份:2021
- 资助金额:
$ 45.76万 - 项目类别:
Studentship Programs
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
- 批准号:
532989-2019 - 财政年份:2020
- 资助金额:
$ 45.76万 - 项目类别:
Postdoctoral Fellowships
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
- 批准号:
10561642 - 财政年份:2019
- 资助金额:
$ 45.76万 - 项目类别:
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
- 批准号:
532989-2019 - 财政年份:2019
- 资助金额:
$ 45.76万 - 项目类别:
Postdoctoral Fellowships
Treating Diabetic Inflammation using AMP-Activated Protein Kinase Activators
使用 AMP 激活的蛋白激酶激活剂治疗糖尿病炎症
- 批准号:
2243045 - 财政年份:2019
- 资助金额:
$ 45.76万 - 项目类别:
Studentship
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
- 批准号:
10359032 - 财政年份:2019
- 资助金额:
$ 45.76万 - 项目类别:
Investigating the therapeutic potential of AMP-activated protein kinase in myotonic dystrophy type 1
研究 AMP 激活蛋白激酶在 1 型强直性肌营养不良中的治疗潜力
- 批准号:
428988 - 财政年份:2019
- 资助金额:
$ 45.76万 - 项目类别:
Studentship Programs